LONDON: Psilocybin, the psychedelic compound in magic mushrooms, may one day be a good treatment for patients with severe depression World Health Organization fail to recover victimisation different therapies, scientists said on Tues.
A small-scale pilot study of psilocybin’s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.
Of 12 patients given the drug, all showed some decrease in symptoms of depression for at least three weeks. Seven continued to show a positive response at 3 months. Five remained in remission on the far side the 3 months.
Robin Carhart-Harris, who junction rectifier the study at Imperial faculty London’s department of medication, said the results, published in the Lancet medicine journal, were striking.
Many patients delineate a profound expertise, he said, and appeared to undergo a shift within the means they perceived the globe.
“But we shouldn’t get carried away with these results,” he told reporters at a briefing in London. “This isn’t a magic bullet. We’re just learning however to try this treatment.”
Magic mushrooms grow worldwide and have been used since earlier period, both for recreation and for spiritual rites.
British researchers led by David Nutt, a professor of neuropsychopharmacology at Imperial, have been exploring the potential of psilocybin to ease severe sorts of depression in those that don’t answer different treatments.
The World Health Organisation estimates that some 350 million people worldwide area unit laid low with depression, a common disturbance characterised by unhappiness, loss of interest or pleasure, tiredness, feelings of guilt or low self-worth, disturbed sleep and appetite, and poor concentration.
Many patients respond to treatment with antidepressants and psychological feature activity medical aid, but around twenty % don’t get higher and area unit classed as having treatment-resistant depression.
Psilocybin acts on the 5-hydroxytryptamine system, suggesting it could be developed for treating depression. But psychoactive medication will conjointly cause unpleasant reactions, including anxiety and psychosis, so Nutt’s team wished to notice out if psychodelic drug may be given safely.
The trial involved six men and six girls, aged between 30 and sixty four, all diagnosed with treatment-resistant depression. They all went through a full screening process before being allowed to participate and that they were totally supported before, during and once they received psychodelic drug.
The patients were given psilocybin capsules throughout 2 dosing sessions, seven days apart.
Blood pressure, heart rate and also the self-reported intensity of the consequences of psilocybin were monitored throughout every session, and the patients were seen by a psychiatrist ensuing day and one, two, three and 5 weeks once the second dose.
Carhart-Harris said no serious aspect effects were reportable throughout the study, although all volunteers same they were slightly anxious before and throughout initial drug administration.
“Psychedelic drugs have potent psychological effects and area unit solely given in our analysis once acceptable safeguards area unit in place,” he said. “I wouldn’t want members of the public thinking they'll treat their own depressions by choosing their own magic mushrooms. That kind of approach can be risky.”
Nutt said the results showed that psychodelic drug “is safe and quick acting, so could – if administered rigorously – have worth for these patients.”
No comments:
Post a Comment